{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:19:22Z","timestamp":1787505562647,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clgc.2024.102264","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T21:21:13Z","timestamp":1731619273000},"page":"102264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost-Effectiveness Analysis of Lenvatinib plus Pembrolizumab or Everolimus as First-Line Treatment for Advanced Renal Cell Carcinoma"],"prefix":"10.1016","volume":"23","author":[{"given":"Huanrui","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5629-0348","authenticated-orcid":false,"given":"Jinhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.clgc.2024.102264_bib0001","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016833","article-title":"Influence of hospital volume on nephrectomy mortality and complications: a systematic review and meta-analysis stratified by surgical type","volume":"7","author":"Hsu","year":"2017","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.clgc.2024.102264_bib0002","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1832348","article-title":"Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions","volume":"9","author":"Incorvaia","year":"2020","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.clgc.2024.102264_bib0003","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.semcancer.2012.06.004","article-title":"Current and future systemic treatments for renal cell carcinoma","volume":"23","author":"Fisher","year":"2013","journal-title":"Semin Cancer Biol"},{"issue":"10","key":"10.1016\/j.clgc.2024.102264_bib0004","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1084\/jem.20181617","article-title":"Kidney cancer: the next decade","volume":"215","author":"Turajlic","year":"2018","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.clgc.2024.102264_bib0005","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clgc.2024.102264_bib0006","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.eururo.2017.11.016","article-title":"Updated European Association of Urology Guidelines: recommendations for the treatment of first-line metastatic clear cell renal cancer","volume":"73","author":"Powles","year":"2018","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.clgc.2024.102264_bib0007","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clgc.2024.102264_bib0008","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.clgc.2024.102264_bib0009","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clgc.2024.102264_bib0010","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.23131","article-title":"E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition","volume":"122","author":"Matsui","year":"2008","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1016\/j.clgc.2024.102264_bib0011","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.19.01598","article-title":"Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.clgc.2024.102264_bib0012","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.clgc.2024.102264_bib0013","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102264_bib0014","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11136-017-1704-4","article-title":"Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma","volume":"27","author":"de Groot","year":"2018","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clgc.2024.102264_bib0015","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8811018","article-title":"The cost-effectiveness of lenvatinib in the treatment of advanced or unresectable hepatocellular carcinoma from a canadian perspective","volume":"2021","author":"Meyers","year":"2021","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.clgc.2024.102264_bib0016","first-page":"834","article-title":"Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States","volume":"21","author":"Benedict","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"10.1016\/j.clgc.2024.102264_bib0017","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3111\/13696998.2014.985789","article-title":"Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US","volume":"18","author":"Perrin","year":"2015","journal-title":"J Med Econ"},{"issue":"2","key":"10.1016\/j.clgc.2024.102264_bib0018","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.0037","article-title":"Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib as first-line treatment of unresectable hepatocellular carcinoma","volume":"4","author":"Su","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.clgc.2024.102264_bib0019","doi-asserted-by":"crossref","first-page":"e32530","DOI":"10.1371\/journal.pone.0032530","article-title":"Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting","volume":"7","author":"Wu","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.clgc.2024.102264_bib0020","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1464-410X.2010.09957.x","article-title":"Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma","volume":"108","author":"Benedict","year":"2011","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.clgc.2024.102264_bib0021","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s40425-018-0440-9","article-title":"Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma","volume":"6","author":"Wu","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2024.102264_bib0022","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3389\/fphar.2020.00619","article-title":"A cost-effectiveness analysis: first-line avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"11","author":"Lu","year":"2020","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102264_bib0023","first-page":"37","article-title":"Health care costs among renal cancer patients using pazopanib and sunitinib","volume":"21","author":"Hansen","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"issue":"9","key":"10.1016\/j.clgc.2024.102264_bib0024","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2013the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clgc.2024.102264_bib0025","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.19.01598","article-title":"Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"J Clin Oncol."}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324002349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324002349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:30:41Z","timestamp":1762551041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324002349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1558767324002349"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102264","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis of Lenvatinib plus Pembrolizumab or Everolimus as First-Line Treatment for Advanced Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102264"}}